Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Altamira Therapeutics Ltd. CYTOF

Healthcare  —  Biotechnology
0.07 0.00 0.00% as of 24 Sep
Market cap
$1.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Altamira Therapeutics Ltd. (CYTOF) Business Profile

Updated before January 2025

Company Overview

Altamira Therapeutics Ltd. (NASDAQ: CYTOF) is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, Altamira has established itself as a pioneer in RNA delivery technology and inner ear therapeutics. The company is led by a team of seasoned professionals, including its CEO, Thomas Meyer, who has extensive experience in the pharmaceutical and biotechnology sectors. Altamira’s mission is to improve the quality of life for patients by addressing critical gaps in treatment options through cutting-edge science and technology.

Core Business Segments

Altamira Therapeutics operates across several key business segments, focusing on the development of RNA delivery platforms, inner ear therapeutics, and other innovative treatment modalities.

RNA Delivery Platforms

Altamira’s flagship technology, OligoPhore™ and SemaPhore™, are proprietary RNA delivery platforms designed to enable the safe and effective delivery of RNA molecules to target cells. These platforms are pivotal in advancing RNA-based therapies for a wide range of diseases, including cancer, inflammatory conditions, and genetic disorders. The company collaborates with pharmaceutical and biotech partners to leverage these platforms for therapeutic development.

Inner Ear Therapeutics

Altamira is a leader in the development of treatments for inner ear disorders. Its AM-125 (Betahistine nasal spray) is being developed for the treatment of acute vertigo, while AM-401 and AM-411 target hearing loss and tinnitus, respectively. These innovative therapies aim to address significant unmet needs in otology, a field with limited treatment options.

Other Therapeutic Areas

In addition to its core focus areas, Altamira is exploring applications of its technologies in other therapeutic domains. The company is actively involved in preclinical and clinical research to expand its pipeline and address diverse medical challenges.

Business Model

Altamira Therapeutics employs a hybrid business model that combines in-house development with strategic partnerships. The company generates revenue through licensing agreements, research collaborations, and milestone payments from its partners. By leveraging its proprietary technologies, Altamira aims to create value for stakeholders while advancing its mission to transform patient care.

Strategic Direction

Altamira’s strategic priorities include:

  • Pipeline Expansion: The company is committed to advancing its clinical and preclinical programs, with a focus on RNA therapeutics and inner ear disorders.
  • Partnership Development: Altamira seeks to establish collaborations with leading pharmaceutical and biotechnology companies to accelerate the development and commercialization of its technologies.
  • Sustainability Goals: The company is dedicated to minimizing its environmental footprint and promoting sustainable practices across its operations.
  • Innovation: Altamira continues to invest in research and development to explore new therapeutic applications and enhance its existing platforms.

Competitive Landscape

Altamira Therapeutics operates in a highly competitive environment, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • RNA Therapeutics: Companies like Moderna, BioNTech, and Alnylam Pharmaceuticals are leaders in RNA-based therapies.
  • Inner Ear Therapeutics: Firms such as Otonomy and Frequency Therapeutics are developing treatments for hearing loss and related conditions.
  • Drug Delivery Platforms: Altamira competes with companies offering advanced drug delivery technologies, including lipid nanoparticles and viral vectors.

Despite the competitive landscape, Altamira differentiates itself through its proprietary technologies and focus on underserved medical needs.

Risk Factors

Altamira Therapeutics faces several risks, including:

  • Regulatory Challenges: The development and approval of new therapies are subject to stringent regulatory requirements, which can delay commercialization.
  • Market Dependence: The company’s success is heavily reliant on the adoption of its products and technologies by the healthcare market.
  • Supply Chain Disruptions: Global supply chain issues could impact the availability of raw materials and manufacturing processes.
  • Financial Risks: As a clinical-stage company, Altamira may face challenges in securing sufficient funding to advance its pipeline.

Recent Developments

Altamira has made significant progress in recent years, including:

  • Clinical Trials: The company has advanced its AM-125 program into late-stage clinical trials, demonstrating promising results for the treatment of acute vertigo.
  • Partnerships: Altamira has entered into strategic collaborations to expand the application of its RNA delivery platforms.
  • Corporate Initiatives: The company has streamlined its operations to focus on its core areas of expertise, enhancing efficiency and resource allocation.

Global developments, such as the COVID-19 pandemic, have underscored the importance of innovative therapies and accelerated the adoption of RNA-based technologies, benefiting Altamira’s strategic positioning.

Investment Considerations

Investors considering Altamira Therapeutics should weigh the following factors:

Strengths

  • Proprietary RNA delivery platforms with broad therapeutic potential.
  • Strong pipeline targeting high-value markets, including inner ear disorders.
  • Experienced leadership team with a track record of innovation.
  • Strategic partnerships that enhance development and commercialization capabilities.

Risks

  • Clinical and regulatory uncertainties associated with drug development.
  • Dependence on external funding to support operations and pipeline advancement.
  • Competitive pressures from established and emerging players in the biotech sector.

Conclusion

Altamira Therapeutics Ltd. is at the forefront of innovation in RNA delivery and inner ear therapeutics. With a robust pipeline, proprietary technologies, and a commitment to addressing unmet medical needs, the company is well-positioned for growth. While challenges remain, Altamira’s strategic direction and focus on innovation provide a strong foundation for future success. Investors seeking exposure to cutting-edge biopharmaceuticals may find Altamira an attractive opportunity, albeit with inherent risks associated with the sector.